dc.contributor.author | Rayner H.C. | |
dc.contributor.author | Larkina M. | |
dc.contributor.author | Wang M. | |
dc.contributor.author | Graham-Brown M. | |
dc.contributor.author | van der Veer S.N. | |
dc.contributor.author | Ecder T. | |
dc.contributor.author | Pisoni R.L. | |
dc.date.accessioned | 2019-08-13T12:10:23Z | |
dc.date.accessioned | 2019-08-13T15:52:52Z | |
dc.date.available | 2019-08-13T12:10:23Z | |
dc.date.available | 2019-08-13T15:52:52Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 1555-9041 | |
dc.identifier.uri | https://dx.doi.org/10.2215/CJN.03280317 | |
dc.identifier.uri | http://hdl.handle.net/11446/1754 | |
dc.description | PubMed ID: 28923831 | en_US |
dc.description.abstract | Background and objectives Uremic pruritus in patients on hemodialysis is associated with depression, lower quality of life, and mortality. We studied the prevalence, awareness, and treatment of pruritus to assess how well this important condition is currently managed internationally. Design, setting, participants, & measurements Data from 35,452 patients on hemodialysis in up to 17 countries from the Dialysis Outcomes and Practice Patterns Study were analyzed to describe pruritus prevalence from 1996 to 2015. Data from 6256 patients and 268 medical directors in 17 countries in 2012–2015 were analyzed to describe predictors, effects, medical directors’ awareness, and treatment of pruritus. Results Patients very much or extremely bothered by itching declined from 28% in 1996 to 18% in 2015. In 2012– 2015, among patients nearly always or always bothered by itching, pruritus had a major effect on work and social life; 18% used no treatment for pruritus, and 17% did not report itching to health care staff. In total, 69% of medical directors underestimated the prevalence of pruritus in their unit. Managing high serum phosphorus and low Kt/V was ranked as the most important intervention, but no relationship was found between these factors and pruritus; 57% of medical directors used oral antihistamines for first-line chronic treatment of pruritus. Gabapentin was used by 45% as first-, second-, or third-line treatment. Nalfurafine was only used in Japan. Conclusions The prevalence of pruritus in people on hemodialysis is decreasing but remains underestimated. Large numbers of patients on hemodialysis with severe pruritus do not receive treatment. There is wide variation in the use of unlicensed medications for the treatment of pruritus. These data provide a benchmark for initiatives to improve the management of uremic pruritus. © 2017 by the American Society of Nephrology. | en_US |
dc.description.sponsorship | King Chulalongkorn Memorial Hospital Agence Nationale de la Recherche National Institutes of Health Amgen Società Italiana di Ematologia Sperimentale National Health and Medical Research Council AstraZeneca Chulalongkorn University National Institute for Health Research Kyowa Hakko Kirin National Health and Medical Research Council: MR/K006665/1 Canadian Institutes of Health Research National Research Council of Thailand | en_US |
dc.description.sponsorship | S.N.v.d.V. is supported by Health e-Research Centre Medical Research Council Research grant MR/K006665/1. The Dialysis Outcomes and Practice Patterns Study (DOPPS) Program is supported by Amgen, Kyowa Hakko Kirin, and Baxter Healthcare. Additional support for specific projects and countries is provided by Amgen, AstraZeneca, the European Renal Association-European Dialysis and Transplant Association, the German Society of Nephrology, Hexal AG, Janssen, the Japanese Society for Peritoneal Dialysis, Keryx, Proteon, Relypsa, Roche, the Società Italiana di Nefrologia, the Spanish Society of Nephrology, and Vifor Fresenius Medical Care Renal Pharma. Public funding and support provided for specific DOPPS projects, ancillary studies, or affiliated research projects are as follows: Australia: the National Health and Medical Research Council; Canada: the Canadian Institutes of Health Research and the Ontario Renal Network; France: Agence Nationale de la Recherche; Thailand: Thailand Research Foundation, the Chulalongkorn University Matching Fund, the King Chulalongkorn Memorial Hospital Matching Fund, and the National Research Council of Thailand; the United Kingdom: the National Institute for Health Research via the Comprehensive Clinical Research Network; and the United States: the National Institutes of Health and the Patient-Centered Outcomes Research Institute. All grants are made to Arbor Research Collaborative for Health and are not to coauthors directly. All support is provided without restrictions on publications. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | American Society of Nephrology | en_US |
dc.identifier.doi | 10.2215/CJN.03280317 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Benchmarking | en_US |
dc.subject | Cyclohexanecarboxylic acids | en_US |
dc.subject | Depression | en_US |
dc.subject | Dialysis | en_US |
dc.subject | Gabapentin | en_US |
dc.subject | Gamma-aminobutyric acid | en_US |
dc.subject | Hemodialysis | en_US |
dc.subject | Histamine antagonists | en_US |
dc.subject | Outcomes | en_US |
dc.subject | Phosphorus | en_US |
dc.subject | Physician executives | en_US |
dc.subject | Prevalence | en_US |
dc.subject | Quality of life | en_US |
dc.subject | Renal dialysis | en_US |
dc.title | International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis | en_US |
dc.type | article | en_US |
dc.relation.journal | Clinical Journal of the American Society of Nephrology | en_US |
dc.department | DBÜ | en_US |
dc.identifier.issue | 12 | en_US |
dc.identifier.volume | 12 | en_US |
dc.identifier.startpage | 2000 | en_US |
dc.identifier.endpage | 2007 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | DBÜ | en_US |